Cencora, Inc. (NYSE:COR) Shares Purchased by Harbour Trust & Investment Management Co

Harbour Trust & Investment Management Co boosted its holdings in shares of Cencora, Inc. (NYSE:COR) by 7.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 10,205 shares of the company’s stock after purchasing an additional 727 shares during the period. Harbour Trust & Investment Management Co’s holdings in Cencora were worth $2,293,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Dynamic Advisor Solutions LLC lifted its holdings in Cencora by 15.2% in the third quarter. Dynamic Advisor Solutions LLC now owns 1,166 shares of the company’s stock valued at $262,000 after acquiring an additional 154 shares during the period. Valeo Financial Advisors LLC increased its stake in shares of Cencora by 5.0% during the 3rd quarter. Valeo Financial Advisors LLC now owns 1,645 shares of the company’s stock valued at $370,000 after acquiring an additional 79 shares during the last quarter. Gateway Investment Advisers LLC raised its holdings in shares of Cencora by 9.0% in the 3rd quarter. Gateway Investment Advisers LLC now owns 4,388 shares of the company’s stock worth $988,000 after purchasing an additional 364 shares during the period. Ritholtz Wealth Management boosted its position in Cencora by 0.8% during the 3rd quarter. Ritholtz Wealth Management now owns 10,560 shares of the company’s stock worth $2,377,000 after purchasing an additional 82 shares during the period. Finally, Retirement Planning Group LLC purchased a new position in Cencora in the 3rd quarter valued at about $251,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on COR. Barclays boosted their target price on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Evercore ISI boosted their target price on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a report on Thursday. Mizuho began coverage on shares of Cencora in a research report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price target for the company. Robert W. Baird upped their price target on shares of Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Finally, Wells Fargo & Company lifted their price target on shares of Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 29th. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $277.90.

Insider Transactions at Cencora

In other news, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total transaction of $5,208,619.44. Following the completion of the transaction, the chairman now directly owns 306,752 shares of the company’s stock, valued at $74,283,064.32. This represents a 6.55 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of the business’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares in the company, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 73,187 shares of company stock valued at $17,790,912 over the last three months. 10.80% of the stock is currently owned by corporate insiders.

Cencora Stock Up 0.7 %

Shares of NYSE:COR opened at $247.94 on Monday. The company has a 50 day moving average of $238.94 and a 200-day moving average of $236.90. Cencora, Inc. has a one year low of $214.77 and a one year high of $262.26. The stock has a market cap of $47.92 billion, a price-to-earnings ratio of 35.27, a P/E/G ratio of 1.49 and a beta of 0.49. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.53.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, sell-side analysts forecast that Cencora, Inc. will post 15.36 earnings per share for the current year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, March 3rd. Shareholders of record on Friday, February 14th will be paid a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.89%. The ex-dividend date is Friday, February 14th. Cencora’s payout ratio is presently 31.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.